8-K
filed November 2, 2022, 7:59 PM ET
CIK 0001709401
other material
confidence high
sentiment negative
materiality 1.00
Rubius Therapeutics, Inc.: restructuring charge — Rubius cuts 82% of staff, CEO and CFO exit, begins strategic review
Rubius Therapeutics, Inc.
- Terminated 42 employees (82% of workforce); expects ~$4.4M in Q4 2022 severance charges.
- CEO Pablo Cagnoni, CFO Jose Carmona, and CLO Maiken Keson-Brookes step down effective Nov 15, 2022.
- Dannielle Appelhans appointed CEO/President and interim CFO; her employment expected to end Jan 31, 2023.
- Board approved plan to review strategic alternatives, including sale or merger of the company.
- Recent termination of $75M credit facility with SLR Investment Corp. cited as factor in financial condition.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.9
Dannielle Appelhans was appointed as Interim Chief Financial Officer and Principal Accounting Officer at Rubius Therapeutics, Inc..
- Action
- will serve as
- Role
- Interim Chief Financial Officer and Principal Accounting Officer
Exact text from the filing
Ms. Appelhans will also serve as the Company’s principal executive officer, and as its interim principal financial officer and principal accounting officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Pablo J. Cagnoni was appointed as Chairman of the Board at Rubius Therapeutics, Inc..
- Action
- appointed
- Role
- Chairman of the Board
Exact text from the filing
Dr. Cagnoni will continue in his role as a member of the Board, and was appointed to serve as Chairman of the Board, effective November 1, 2022
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dannielle Appelhans was appointed as Chief Executive Officer and President at Rubius Therapeutics, Inc..
- Action
- appointed
- Role
- Chief Executive Officer and President
Exact text from the filing
the Board has appointed Dannielle Appelhans, age 39, Chief Operating Officer of the Company, as the Company’s Chief Executive Officer and President, effective upon the Separation Date
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Maiken Keson-Brookes departed as Chief Legal Officer at Rubius Therapeutics, Inc..
- Action
- stepped down
- Role
- Chief Legal Officer
Exact text from the filing
Maiken Keson-Brookes, Chief Legal Officer and corporate secretary of the Company, have negotiated a separation of service with the Company, effective November 15, 2022
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Noubar Afeyan resigned as Chairman of the Board at Rubius Therapeutics, Inc..
- Action
- resigned
- Role
- Chairman of the Board
Exact text from the filing
Dr. Noubar Afeyan, Chairman of the Board of Rubius, resigned from the Board and will continue as a Board observer.
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
Rubius Therapeutics, Inc. announced a restructuring with charges of approximately $4.4 million (42 of its employees (representing 82% of its current employee base)).
- Type
- restructuring
- Charge
- approximately $4.4 million
- Headcount
- 42 of its employees (representing 82% of its current employee base)
Exact text from the filing
On November 2, 2022, Rubius Therapeutics, Inc. (the “Company”) announced that, in light of the Company’s financial condition, including the recently disclosed repayment and termination of its $75 million credit facility with SLR Investment Corp., and the early stage of its programs, its Board of Directors (the “Board”) approved a plan to review strategic alternatives, including a sale or merger of the Company or one or more sales of its assets, and to significantly and immediately reduce its operations (the “Plan”). In connection with this Plan, the Company has terminated 42 of its employees (representing 82% of its current employee base), leaving a core team of individuals to lead the strategic review process. The Company expects that these measures will reduce its operating expenses with the goal of allowing the Company to pursue any viable strategic alternatives. As a result of the Plan, the Company estimates that it will incur charges of approximately $4.4 million in the fourth qua
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.